243 related articles for article (PubMed ID: 33664308)
1. MR-proADM as prognostic factor of outcome in COVID-19 patients.
Sozio E; Tascini C; Fabris M; D'Aurizio F; De Carlo C; Graziano E; Bassi F; Sbrana F; Ripoli A; Pagotto A; Giacinta A; Gerussi V; Visentini D; De Stefanis P; Merelli M; Saeed K; Curcio F
Sci Rep; 2021 Mar; 11(1):5121. PubMed ID: 33664308
[TBL] [Abstract][Full Text] [Related]
2. The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study.
Gregoriano C; Koch D; Kutz A; Haubitz S; Conen A; Bernasconi L; Hammerer-Lercher A; Saeed K; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 Apr; 59(5):995-1004. PubMed ID: 33554516
[TBL] [Abstract][Full Text] [Related]
3. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center.
Benedetti I; Spinelli D; Callegari T; Bonometti R; Molinaro E; Novara E; Cassinari M; Frino C; Guaschino R; Boverio R; Lauritano EC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1743-1751. PubMed ID: 33629344
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study.
Montrucchio G; Sales G; Rumbolo F; Palmesino F; Fanelli V; Urbino R; Filippini C; Mengozzi G; Brazzi L
PLoS One; 2021; 16(2):e0246771. PubMed ID: 33556140
[TBL] [Abstract][Full Text] [Related]
5. Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study.
Dres M; Hausfater P; Foissac F; Bernard M; Joly LM; Sebbane M; Philippon AL; Gil-Jardiné C; Schmidt J; Maignan M; Treluyer JM; Roche N
Int J Chron Obstruct Pulmon Dis; 2017; 12():1047-1056. PubMed ID: 28408815
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
[TBL] [Abstract][Full Text] [Related]
7. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin.
Sozio E; Moore NA; Fabris M; Ripoli A; Rumbolo F; Minieri M; Boverio R; Rodríguez Mulero MD; Lainez-Martinez S; Martínez Martínez M; Calvo D; Gregoriano C; Williams R; Brazzi L; Terrinoni A; Callegari T; Hernández Olivo M; Esteban-Torrella P; Calcerrada I; Bernasconi L; Kidd SP; Sbrana F; Miguens I; Gordon K; Visentini D; Legramante JM; Bassi F; Cortes N; Montrucchio G; Di Lecce VN; Lauritano EC; García de Guadiana-Romualdo L; González Del Castillo J; Bernal-Morell E; Andaluz-Ojeda D; Schuetz P; Curcio F; Tascini C; Saeed K
Respir Res; 2022 Aug; 23(1):221. PubMed ID: 36031619
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.
Lo Sasso B; Gambino CM; Scichilone N; Giglio RV; Bivona G; Scazzone C; Muratore R; Milano S; Barbagallo M; Agnello L; Ciaccio M
Lab Med; 2021 Sep; 52(5):493-498. PubMed ID: 33928380
[TBL] [Abstract][Full Text] [Related]
9. MR-proADM as marker of endotheliitis predicts COVID-19 severity.
García de Guadiana-Romualdo L; Calvo Nieves MD; Rodríguez Mulero MD; Calcerrada Alises I; Hernández Olivo M; Trapiello Fernández W; González Morales M; Bolado Jiménez C; Albaladejo-Otón MD; Fernández Ovalle H; Conesa Hernández A; Azpeleta Manrique E; Consuegra-Sánchez L; Nogales Martín L; Conesa Zamora P; Andaluz-Ojeda D
Eur J Clin Invest; 2021 May; 51(5):e13511. PubMed ID: 33569769
[TBL] [Abstract][Full Text] [Related]
10. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.
Christ-Crain M; Morgenthaler NG; Struck J; Harbarth S; Bergmann A; Müller B
Crit Care; 2005; 9(6):R816-24. PubMed ID: 16356231
[TBL] [Abstract][Full Text] [Related]
11. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.
Montrucchio G; Sales G; Balzani E; Lombardo D; Giaccone A; Cantù G; D'Antonio G; Rumbolo F; Corcione S; Simonetti U; Bonetto C; Zanierato M; Fanelli V; Filippini C; Mengozzi G; Brazzi L
Front Med (Lausanne); 2023; 10():1122367. PubMed ID: 37035317
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of mid-regional proadrenomedullin levels in the resuscitation phase of severely burned patients and its utility in early sepsis detection.
Flores E; Estébanez B; Quintana M; Fernández-Puntero B; Nanwani K; Cachafeiro L; Martínez JR; Agrifoglio A; Sánchez-Sánchez M
Burns; 2024 Aug; 50(6):1519-1527. PubMed ID: 38570251
[TBL] [Abstract][Full Text] [Related]
14. MR- proADM to detect specific types of organ failure in infection.
Andrés C; Andaluz-Ojeda D; Cicuendez R; Nogales L; Martín S; Martin-Fernandez M; Almansa R; Calvo D; Esteban-Velasco MC; Vaquero-Roncero LM; Ríos-Llorente A; Sanchez-Barrado E; Muñoz-Bellvís L; Aldecoa C; Bermejo-Martin JF
Eur J Clin Invest; 2020 Jun; 50(6):e13246. PubMed ID: 32307701
[TBL] [Abstract][Full Text] [Related]
15. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score.
Travaglino F; De Berardinis B; Magrini L; Bongiovanni C; Candelli M; Silveri NG; Legramante J; Galante A; Salerno G; Cardelli P; Di Somma S
BMC Infect Dis; 2012 Aug; 12():184. PubMed ID: 22874067
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
[TBL] [Abstract][Full Text] [Related]
17. MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy.
Falkentoft AC; Rørth R; Iversen K; Høfsten DE; Kelbæk H; Holmvang L; Frydland M; Schoos MM; Helqvist S; Axelsson A; Clemmensen P; Jørgensen E; Saunamäki K; Tilsted HH; Pedersen F; Torp-Pedersen C; Kofoed KF; Goetze JP; Engstrøm T; Køber L
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29776961
[TBL] [Abstract][Full Text] [Related]
18. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.
Elke G; Bloos F; Wilson DC; Brunkhorst FM; Briegel J; Reinhart K; Loeffler M; Kluge S; Nierhaus A; Jaschinski U; Moerer O; Weyland A; Meybohm P;
Crit Care; 2018 Mar; 22(1):79. PubMed ID: 29562917
[TBL] [Abstract][Full Text] [Related]
19. Association of midregional proadrenomedullin with coronary artery stenoses, soft atherosclerotic plaques and coronary artery calcium.
Roos M; Schuster T; Ndrepepa G; Baumann M; Lutz J; Braun S; Martinof S; Schömig A; Heemann U; Kastrati A; Hausleiter J
Heart Vessels; 2012 Jul; 27(4):352-9. PubMed ID: 21725669
[TBL] [Abstract][Full Text] [Related]
20. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
